Which of the following is a hormonal cancer therapy?

Which of the following is a hormonal cancer therapy?

• A. Anastrozole (Arimidex)
• B. Rituximab (Rituxan)
• C. Cetuximab (Erbitux)
• D. Bevacizumab (Avastin)

Answer: (A)

Anastrozole (Arimidex) is a hormonal cancer therapy specifically classified as an aromatase inhibitor. It works by decreasing the amount of estrogen the body makes, which can help slow or stop the growth of certain types of breast tumors that depend on estrogen for their growth. This makes it particularly effective in treating hormone receptor-positive breast cancer in postmenopausal women. The other options presented are monoclonal antibodies or targeted therapies that are not classified as hormonal therapies. Rituximab, for instance, targets CD20 on B cells and is used mainly for certain leukemias and lymphomas. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used primarily in colorectal cancer and head and neck cancer. Bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit tumor blood supply in various cancers. Each of these agents operates through mechanisms distinct from hormonal modulation, focusing instead on the immune response or specific growth factor signaling pathways.

Anastrozole (Arimidex) is a hormonal cancer therapy specifically classified as an aromatase inhibitor. It works by decreasing the amount of estrogen the body makes, which can help slow or stop the growth of certain types of breast tumors that depend on estrogen for their growth. This makes it particularly effective in treating hormone receptor-positive breast cancer in postmenopausal women.

The other options presented are monoclonal antibodies or targeted therapies that are not classified as hormonal therapies. Rituximab, for instance, targets CD20 on B cells and is used mainly for certain leukemias and lymphomas. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used primarily in colorectal cancer and head and neck cancer. Bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit tumor blood supply in various cancers. Each of these agents operates through mechanisms distinct from hormonal modulation, focusing instead on the immune response or specific growth factor signaling pathways.